MedTrace Logo

Organ Motion and Early Tumor Response Measurement

NCT02139488 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2019-06-27

No results posted yet for this study

Summary

To quantify motion based variation of the target volume of the primary tumor over the course of chemoradiotherapy in esophageal cancer patients, and to use this information to calculate appropriate PTV (planning target volume) margins according to the margins recipe for patients receiving trimodality (neoadjuvant chemoradiation and surgery) or definitive chemoradiation in order to personalize radiation treatment, resulting in either better target coverage or a reduction in normal tissue radiation exposure.

Conditions

  • Esophageal Cancer
  • Chemoradiation

Interventions

OTHER

Fiducial markers

OTHER

Fiducial markers, Pet and MRI

Insertion of Fiducial markers in esophageal wall.

Sponsors & Collaborators

  • The Netherlands Cancer Institute

    lead OTHER

Principal Investigators

  • Francine Voncken, MD · NKI-AvL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-18
Primary Completion
2018-12-31
Completion
2018-12-31

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02139488 on ClinicalTrials.gov